메뉴 건너뛰기




Volumn 32, Issue 1, 2017, Pages 22-27

Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials

Author keywords

adverse reaction; fasting blood glucose; insulin dose; meta analysis; sodium glucose co transporter 2; type 1 diabetes mellitus; urine glucose

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85021810641     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.24920/J1001-9242.2007.003     Document Type: Article
Times cited : (16)

References (17)
  • 1
    • 78651087067 scopus 로고    scopus 로고
    • The changing epidemiology of type 1 diabetes: why is it going through the roof?
    • Vehik, K, Dabelea, D, The changing epidemiology of type 1 diabetes: why is it going through the roof?. Diabetes Metab Res Rev 27 (2011), 3–13.
    • (2011) Diabetes Metab Res Rev , vol.27 , pp. 3-13
    • Vehik, K.1    Dabelea, D.2
  • 2
    • 84921374064 scopus 로고    scopus 로고
    • The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
    • Vallon, V, The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66 (2015), 255–270.
    • (2015) Annu Rev Med , vol.66 , pp. 255-270
    • Vallon, V.1
  • 3
    • 84946497765 scopus 로고    scopus 로고
    • Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes
    • Saulsberry, WJ, Coleman, CI, Mearns, ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract 69 (2015), 1221–1235.
    • (2015) Int J Clin Pract , vol.69 , pp. 1221-1235
    • Saulsberry, W.J.1    Coleman, C.I.2    Mearns, E.S.3
  • 4
    • 0021776150 scopus 로고
    • Diabetes mellitus. Report of a WHO Study Group
    • Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 727 (1985), 1–113.
    • (1985) World Health Organ Tech Rep Ser , vol.727 , pp. 1-113
  • 5
    • 84934442921 scopus 로고    scopus 로고
    • Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study
    • Henry, RR, Rosenstock, J, Edelman, S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38 (2015), 412–419.
    • (2015) Diabetes Care , vol.38 , pp. 412-419
    • Henry, R.R.1    Rosenstock, J.2    Edelman, S.3
  • 6
    • 84942258219 scopus 로고    scopus 로고
    • Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
    • Pieber, TR, Famulla, S, Eilbracht, J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17 (2015), 928–935.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 928-935
    • Pieber, T.R.1    Famulla, S.2    Eilbracht, J.3
  • 7
    • 84939621365 scopus 로고    scopus 로고
    • Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes
    • Sands, AT, Zambrowicz, BP, Rosenstock, J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38 (2015), 1181–1188.
    • (2015) Diabetes Care , vol.38 , pp. 1181-1188
    • Sands, A.T.1    Zambrowicz, B.P.2    Rosenstock, J.3
  • 8
    • 84934446360 scopus 로고    scopus 로고
    • Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
    • Bell, DS, Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol, 2015, 2015, 676191.
    • (2015) Case Rep Endocrinol , vol.2015 , pp. 676191
    • Bell, D.S.1
  • 9
    • 84887331142 scopus 로고    scopus 로고
    • Canagliflozin: improving diabetes by making urine sweet
    • Vouyiouklis, M, Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med 80 (2013), 683–687.
    • (2013) Cleve Clin J Med , vol.80 , pp. 683-687
    • Vouyiouklis, M.1
  • 10
    • 77949680683 scopus 로고    scopus 로고
    • The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews
    • Kirkham, JJ, Dwan, KM, Altman, DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ, 340, 2010, c365.
    • (2010) BMJ , vol.340 , pp. c365
    • Kirkham, J.J.1    Dwan, K.M.2    Altman, D.G.3
  • 11
    • 84867559501 scopus 로고    scopus 로고
    • Relationship between fasting and 2-hour postprandial plasma glucose levels and vascular complications in patients with type 2 diabetes mellitus
    • Tanaka, M, Relationship between fasting and 2-hour postprandial plasma glucose levels and vascular complications in patients with type 2 diabetes mellitus. J Int Med Res 40 (2012), 1295–1303.
    • (2012) J Int Med Res , vol.40 , pp. 1295-1303
    • Tanaka, M.1
  • 13
    • 84978976076 scopus 로고    scopus 로고
    • Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis
    • Palmer, SC, Mavridis, D, Nicolucci, A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
    • (2016) JAMA , vol.316 , pp. 313-324
    • Palmer, S.C.1    Mavridis, D.2    Nicolucci, A.3
  • 14
    • 84959917974 scopus 로고    scopus 로고
    • The changing therapeutic armamentarium for patients with type 1 diabetes
    • Comee, M, Peters, A, The changing therapeutic armamentarium for patients with type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 23 (2016), 106–110.
    • (2016) Curr Opin Endocrinol Diabetes Obes , vol.23 , pp. 106-110
    • Comee, M.1    Peters, A.2
  • 15
    • 84951905769 scopus 로고    scopus 로고
    • SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
    • Scheen, AJ, SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 14 (2015), 1879–1904.
    • (2015) Expert Opin Drug Saf , vol.14 , pp. 1879-1904
    • Scheen, A.J.1
  • 16
    • 84930580133 scopus 로고    scopus 로고
    • Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
    • Hinnen, D, Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 6 (2015), 92–102.
    • (2015) Ther Adv Endocrinol Metab , vol.6 , pp. 92-102
    • Hinnen, D.1
  • 17
    • 85007514629 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
    • Handelsman, Y, Henry, RR, Bloomgarden, ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22 (2016), 753–762.
    • (2016) Endocr Pract , vol.22 , pp. 753-762
    • Handelsman, Y.1    Henry, R.R.2    Bloomgarden, Z.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.